// App-Quantinova.ai

: Comparison of LAMA/LABA vs ICS/LABA in high risk COPD patients: Pre-specified analysis on lung function and health status from the IMPACT trial

Researchers

Presenter

  • David A Lipson

Principal Investigators

  • Frank Barnhart

  • Isabelle Boucot

  • Courtney Crim

  • Noushin Brealey

  • Gerard J Criner

  • Mark Dransfield

  • David M.G Halpin

  • Sally Kilbride

  • Meilan K Han

  • Peter Lange

  • David A Lomas

  • Fernando J Martinez

  • Dave Singh

  • Ian Naya Naya

  • Christine Elaine Jones

  • Robert Wise

Medical Centers

  • GSK, King of Prussia and Perelman School of Medicine, University of Pennsylvania, Philadelphia, United States of America

  • GSK, King of Prussia and Perelman School of Medicine, University of Pennsylvania, Philadelphia, United States of America

  • Global Respiratory Franchise, GSK, Brentford, Middlesex, United Kingdom,

  • GlaxoSmithKline, Research Triangle Park, NC, United States.

  • GlaxoSmithKline, Uxbridge, United Kingdom

  • Lewis Katz School of Medicine at Temple University, Philadelpha , United States of America

  • Division of Pulmonary, Allergy, and Critical Care Medicine, Lung Health Center, University of Alabama at Birmingham, Birmingham, AL, United States,

  • Department of Gastroenterology, Royal Devon and Exeter Hospital, Exeter, United Kingdom

  • University of Copenhagen, Copenhagen E, Denmark

  • UCL Respiratory, University College London, London, United Kingdom

  • NewYork-Presbyterian Hospital/Weill Cornell Medical Center, New York, United States of America

  • Centre for Respiratory Medicine and Allergy, Institute of Inflammation and Repair, Manchester Academic Health Science Centre, The University of Manchester; University Hospital of South Manchester, NHS Foundation Trust, Manchester, United Kingdom

  • Division of Pulmonary and Critical Care, School of Medicine, Johns Hopkins University, Baltimore, United States of America

Locations

  • United States

  • United Kingdom

  • Denmark

Companies

  • N/A

Study Components

Therapeutic Area

  • Pulmonary/Respiratory Diseases

Disease

  • Chronic obstructive pulmonary disease

Biomarkers

  • Complement Factor B

Drug/Treatment

  • fluticasone furoate/umeclidinium/vilanterol

Outcome

  • N/A

Study Design

  • Randomized

  • Double Blind/Blinded

  • Multicenteric

  • Parallel Group

Phase

  • III

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved